Skip to main content
Caplight Logo









NuCyRNA Therapeutics

NuCyRNA Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.nucyrnatx.com/

Last Round

Grant

Jun 12, 2025

Total Funding Raised

$500,000

Company Overview

NuCyRNA Therapeutics is a biotechnology company developing RNA-targeting oligonucleotide therapeutics to address neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oligonucleotide therapeuticsRNA-targetingneurodegenerative diseaseALSantisense oligonucleotideASOCNS disordersdrug discoverybiotechgene knockdowndual-targetingpreclinical researchRNA medicinetherapeutic platformbiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NuCyRNA Therapeutics Comparables

Compare NuCyRNA Therapeutics with similar companies based on industry and business-model similarity.

NuCyRNA Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Trace Neuroscience
85%
QurAlis
76%
Novartis
68%

NuCyRNA Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 12, 2025
SeedOct 30, 2024
AcceleratorMar 18, 2024

Key People

Founding team and executive leadership

Damon Wang

Co-Founder & CEO

Founding Team

NuCyRNA Therapeutics Investors

Notable investors and investment history

NuCyRNA Therapeutics investors
InvestorRounds
Harvard Innovation LabsAccelerator
Target ALSGrant
Ono Venture Investment, Inc.Seed
Mission BioCapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 12, 2025

    Received grant from Target ALS.

  • Oct 30, 2024

    $500K round led by Mission BioCapital.

NuCyRNA Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NuCyRNA Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NuCyRNA Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range3
Year Founded2023
Last FundingJun 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?